LivaNova PLC (NASDAQ:LIVN) has been given an average rating of “Buy” by the six research firms that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $101.00.
LIVN has been the subject of several research reports. Piper Sandler reduced their target price on shares of LivaNova from $99.00 to $98.00 and set an “overweight” rating for the company in a research note on Tuesday, June 1st. Zacks Investment Research upgraded shares of LivaNova from a “sell” rating to a “hold” rating in a research note on Wednesday, August 4th. Needham & Company LLC increased their price target on shares of LivaNova from $104.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, August 20th. Finally, Robert W. Baird increased their price target on shares of LivaNova from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 17th. They noted that the move was a valuation call.
In other news, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 1st. The shares were sold at an average price of $82.40, for a total transaction of $82,400.00. Following the completion of the sale, the director now owns 31,630 shares of the company’s stock, valued at $2,606,312. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.37% of the company’s stock.
LIVN stock traded up $0.10 during mid-day trading on Tuesday, reaching $83.60. 121,333 shares of the stock traded hands, compared to its average volume of 401,879. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 0.41. LivaNova has a 52 week low of $41.07 and a 52 week high of $90.25. The business has a 50-day moving average of $82.23 and a two-hundred day moving average of $81.35. The firm has a market capitalization of $4.10 billion, a PE ratio of -10.73 and a beta of 0.90.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, July 28th. The company reported $0.52 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.19. LivaNova had a negative net margin of 37.15% and a positive return on equity of 8.44%. The business had revenue of $264.50 million during the quarter, compared to analysts’ expectations of $241.73 million. On average, equities research analysts anticipate that LivaNova will post 1.57 EPS for the current fiscal year.
LivaNova Company Profile
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products.
Read More: What is the S&P/ASX 200 Index?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.